[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS50928B - Gcsf konjugati - Google Patents

Gcsf konjugati

Info

Publication number
RS50928B
RS50928B YUP-543/01A YUP54301A RS50928B RS 50928 B RS50928 B RS 50928B YU P54301 A YUP54301 A YU P54301A RS 50928 B RS50928 B RS 50928B
Authority
RS
Serbia
Prior art keywords
integral
conjugate
gcsf conjugates
alkyl
independent
Prior art date
Application number
YUP-543/01A
Other languages
English (en)
Inventor
Pascal Sebastian Bailon
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of YU54301A publication Critical patent/YU54301A/sh
Publication of RS50928B publication Critical patent/RS50928B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyethers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Fiziološki aktivan konjugat, naznačen time što ima formulugde je G faktor stimulacije kolonije granulocita bez amino grupe ili njegovih grupa koje formiraju amidnu vezu sa polietilen glikol grupom u konjugatu; R je C1-C6 alkil; n je integral od 420 do 550; i m je integral 1-5.Prijava sadrži još 2 nezavisna i 17 zavisnih patentnih zahteva.
YUP-543/01A 1999-01-29 2000-01-19 Gcsf konjugati RS50928B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11791799P 1999-01-29 1999-01-29

Publications (2)

Publication Number Publication Date
YU54301A YU54301A (sh) 2003-10-31
RS50928B true RS50928B (sr) 2010-08-31

Family

ID=22375505

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-543/01A RS50928B (sr) 1999-01-29 2000-01-19 Gcsf konjugati

Country Status (26)

Country Link
US (4) US20030130193A1 (sr)
EP (1) EP1157037B1 (sr)
JP (1) JP2002540065A (sr)
KR (1) KR100689212B1 (sr)
CN (1) CN1376164A (sr)
AT (1) ATE246202T1 (sr)
AU (1) AU2618500A (sr)
BG (1) BG65213B1 (sr)
BR (1) BR0007781A (sr)
CA (1) CA2361766C (sr)
CZ (1) CZ300546B6 (sr)
DE (1) DE60004172T2 (sr)
DK (1) DK1157037T3 (sr)
EA (2) EA200400067A1 (sr)
ES (1) ES2204509T3 (sr)
HK (1) HK1049673A1 (sr)
HU (1) HU228488B1 (sr)
IL (1) IL144361A0 (sr)
MX (1) MXPA01007609A (sr)
NO (1) NO331787B1 (sr)
NZ (1) NZ513113A (sr)
PT (1) PT1157037E (sr)
RS (1) RS50928B (sr)
SK (1) SK286898B6 (sr)
WO (1) WO2000044785A1 (sr)
ZA (1) ZA200105932B (sr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1157037E (pt) * 1999-01-29 2003-12-31 Hoffmann La Roche Conjugados de gcsf
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
AU2001290312A1 (en) 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
EP2298354B1 (en) * 2001-10-10 2014-03-19 ratiopharm GmbH Remodelling and glycoconjugation of interferon-beta
PT2279755E (pt) * 2001-10-10 2014-06-04 Ratiopharm Gmbh Remodelação e glicoconjugação do factor de crescimento de fibroblastos (fgf)
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
HUP0500997A2 (en) * 2001-11-20 2007-11-28 Pharmacia Corp Chemically-modified human growth hormone conjugates
CA2492775C (en) 2002-07-24 2011-06-21 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
CA2536152A1 (en) * 2003-08-22 2005-03-03 The Council Of The Queensland Institute Of Medical Research G-csf derivative for inducing immunological tolerance
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060174362A1 (en) * 2005-02-01 2006-08-03 Origen Therapeutics, Inc. Long-term culture of avian primordial germ cells (PGCs)
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
RU2007149238A (ru) 2005-06-01 2009-07-20 Максиджен Холдингз Лтд. (Ky) Пегилированные полипептиды гксф и способы их получения
PL2279758T3 (pl) 2005-06-16 2015-07-31 Nektar Therapeutics Koniugaty mające degradowalne połączenie oraz odczynniki polimerowe użyteczne w wytwarzaniu takich koniugatów
BRPI0614257A2 (pt) * 2005-08-04 2011-03-15 Nektar Therapeutics Al Corp conjugados de uma porção de g-csf e um polìmero
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2007112924A (ja) * 2005-10-21 2007-05-10 National Institute For Materials Science 高分子架橋剤及びこの架橋剤を用いたリポソーム又は細胞の架橋体
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN101002943B (zh) * 2006-01-17 2012-02-01 中国科学院过程工程研究所 支链peg-gcsf和peg-gmcsf结合物及其制备方法
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US20100316631A1 (en) * 2006-10-19 2010-12-16 The Uab Research Foundation Water Soluble Curcumin-Based Compounds
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
JP2008125952A (ja) * 2006-11-24 2008-06-05 National Institute For Materials Science 複合架橋体
CN101245109B (zh) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CN101352573B (zh) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
US8629104B2 (en) 2008-02-18 2014-01-14 Jiangsu Hengrui Medicine Co. Ltd. G-CSF and water-soluble polymer conjugate
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
RU2409669C9 (ru) 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
CA2736141C (en) 2008-09-23 2018-03-20 F. Hoffmann-La Roche Ag Purification of erythropoietin
US9587006B2 (en) 2010-02-11 2017-03-07 Hoffmann-La Roche Inc. IGF-I poly (ethylene glycol) conjugates
CA2808748C (en) 2010-09-14 2018-09-11 Roberto Falkenstein Method for purifying pegylated erythropoietin
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
SG11201811553UA (en) 2016-07-15 2019-01-30 Hoffmann La Roche Method for purifying pegylated erythropoietin
EP3694535A4 (en) 2017-10-11 2021-07-28 Elanco US Inc. VARIANTS OF PORCINE G-CSF AND THEIR USES
SG11202005952TA (en) 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition
EP3731872B1 (en) 2017-12-29 2021-11-24 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
CN111741770A (zh) 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
EP4267592A1 (en) * 2020-12-23 2023-11-01 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1609546A (en) * 1925-11-19 1926-12-07 Petroleum Rectifying Co Process of separating water from emulsions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4514497B1 (en) * 1983-12-30 1998-02-24 Novagene Inc Modified live pseudorabies viruses
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR0176625B1 (ko) * 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
PT1157037E (pt) * 1999-01-29 2003-12-31 Hoffmann La Roche Conjugados de gcsf

Also Published As

Publication number Publication date
CN1376164A (zh) 2002-10-23
NO20013700D0 (no) 2001-07-27
EP1157037B1 (en) 2003-07-30
CZ300546B6 (cs) 2009-06-10
HU228488B1 (en) 2013-03-28
WO2000044785A1 (en) 2000-08-03
YU54301A (sh) 2003-10-31
EA200400067A1 (ru) 2004-04-29
SK286898B6 (sk) 2009-07-06
EA004685B1 (ru) 2004-06-24
DE60004172T2 (de) 2004-04-22
HUP0203652A2 (hu) 2003-03-28
KR20020007296A (ko) 2002-01-26
HUP0203652A3 (en) 2005-01-28
US20030130193A1 (en) 2003-07-10
BR0007781A (pt) 2002-02-05
ZA200105932B (en) 2002-10-18
EP1157037A1 (en) 2001-11-28
IL144361A0 (en) 2002-05-23
BG65213B1 (bg) 2007-07-31
BG105851A (en) 2002-06-28
ATE246202T1 (de) 2003-08-15
MXPA01007609A (es) 2003-06-24
DE60004172D1 (de) 2003-09-04
NO20013700L (no) 2001-09-25
ES2204509T3 (es) 2004-05-01
AU2618500A (en) 2000-08-18
US20050196378A1 (en) 2005-09-08
US20080287659A1 (en) 2008-11-20
SK10352001A3 (sk) 2002-06-04
CA2361766A1 (en) 2000-08-03
PT1157037E (pt) 2003-12-31
HK1049673A1 (zh) 2003-05-23
PL363117A1 (en) 2004-11-15
US20070219356A1 (en) 2007-09-20
JP2002540065A (ja) 2002-11-26
NZ513113A (en) 2004-03-26
CA2361766C (en) 2011-12-06
CZ20012654A3 (cs) 2002-05-15
NO331787B1 (no) 2012-04-02
KR100689212B1 (ko) 2007-03-09
DK1157037T3 (da) 2003-11-24
EA200100838A1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
RS50928B (sr) Gcsf konjugati
BR9510080A (pt) Lipopoliamina sob forma D,L, ou DL ou um de seus sais e composição farmacêutica
PT923566E (pt) Profarmacos de base polimerica de elevado peso molecular
BR9608743A (pt) Polímeros sol·veis em água e composições dos mesmos
RS49533B (sr) Interferonski konjugati
RS50144B (sr) Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c
BG103590A (en) Pesticide 1-arylpyrazols
MX9803761A (es) Nuevos agentes de transfeccion y sus aplicaciones farmaceuticas.
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
TR199901471T2 (xx) Pestisidal 1-aril ve piridilpirazol t�revleri.
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
BG103657A (en) New modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminebenzene and methods for their prepration
HK1069285A1 (en) Improved synthesis of polyanhyrides
RS49700B (sr) Nimesulidni gelni sistemi za topikalnu primenu
HUP9902465A1 (hu) Új amidínium-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE306900T1 (de) Verdickungssystem für kosmetische zusammensetzungen
ATE250610T1 (de) Kaliumkanal-blockierende mittel
NZ517872A (en) Multidrug efflux pumps
SE0101344D0 (sv) Iron powder composition
MX9603199A (es) Antagonistas de receptores a endotelina.
ATE302757T1 (de) Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität
NO20014814L (no) Bifunksjonelle polymerer
AU2001270562A1 (en) Agent for colouring keratin-containing fibres